Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 63
Filter
Add more filters










Publication year range
1.
Epidemiology ; 12(6): 719-26, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11679802

ABSTRACT

Large regional variations in bladder cancer rates have been observed for numerous decades in the United States and persist to date. We examined the incidence rates of bladder cancer by geographic region among U.S. male health professionals to determine whether diet or other lifestyle factors can account for variations observed. During 12 years of follow-up, 328 cases of bladder cancer were diagnosed in the Health Professionals Follow-up Study cohort. We inquired about diet, lifetime history of smoking, race, marital status, and other nondietary factors using mailed questionnaires. An elevated risk of bladder cancer was observed in the Northeast compared with the West [relative risk (RR) = 1.71, 95% confidence interval (CI) = 1.23-2.39], which was slightly attenuated after controlling for smoking (RR = 1.65, 95% CI = 1.18-2.30). Smoking patterns, diet, and other lifestyle factors could not account for all of the elevated bladder cancer risk in the Northeast. Bladder cancer risk was highest among men who had a long residency in the Northeast compared with a long residency in the West (RR = 1.77, 95% CI = 1.15-2.71, adjusted for smoking). Diet and other known characteristics do not appear to be responsible for the regional variations in bladder cancer rates in the United States.


Subject(s)
Health Personnel/statistics & numerical data , Urinary Bladder Neoplasms/epidemiology , Adult , Aged , Cohort Studies , Diet , Drinking , Humans , Incidence , Life Style , Male , Middle Aged , New England/epidemiology , Prospective Studies , Risk Factors , Smoking/adverse effects , Smoking/epidemiology , Socioeconomic Factors , Surveys and Questionnaires , United States/epidemiology , Urinary Bladder Neoplasms/ethnology
2.
Hum Genet ; 109(2): 146-51, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11511919

ABSTRACT

Peroxisome proliferator activated receptor gamma (PPARgamma) is a nuclear hormone receptor that has been shown to regulate differentiation and cell growth. Studies of the differentiative effects of PPARgamma agonists on several cancer cell lines led to the hypothesis that dysfunction of PPARgamma contributes to tumorigenesis. These functional observations were strengthened by genetic evidence: somatic loss-of-function mutations in PPARG, encoding PPARgamma, in sporadic colorectal carcinomas and somatic translocation of PAX8 and PPARG in follicular thyroid carcinoma. Recently overrepresentation of the H449H variant was found in a cohort of American patients with glioblastoma multiforme. The glioblastoma multiforme data suggest that PPARG contributes common, low-penetrance alleles for cancer susceptibility. To test this hypothesis in a broader range of cancers we examined a series of carcinomas of the cervix, endometrium, ovary, prostate, and kidney for germline sequence variation in PPARG. In addition to the two common sequence variants, P12A and H449H, there were five other sequence variants. P12A alleles were underrepresented in renal cell carcinoma patients compared to country-of-origin race-matched controls (3.75% vs. 12.1%, P<0.04). In contrast, the H449H variant was overrepresented in individuals with endometrial carcinoma compared to controls (14.4% vs. 6.25%, P<0.02). These observations lend genetic evidence consistent with our hypothesis that PPARG serves as a common, low-penetrance susceptibility gene for cancers of several types, especially those epidemiologically associated with obesity and fat intake.


Subject(s)
DNA-Binding Proteins/genetics , Genetic Variation , Neoplasms/genetics , Polymorphism, Genetic/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Transcription Factors/genetics , Adenocarcinoma/genetics , Alleles , Carcinoma, Renal Cell/genetics , DNA Mutational Analysis , DNA, Neoplasm/analysis , Endometrial Neoplasms/genetics , Female , Gene Frequency/genetics , Humans , Kidney Neoplasms/genetics , Male , Penetrance , Polymerase Chain Reaction
4.
J Nutr ; 131(6): 1746-52, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11385062

ABSTRACT

We previously demonstrated that the castration of male rats profoundly increases hepatic lycopene compared with intact controls. Here we further characterized the role of testosterone in modulating hepatic lycopene accumulation and isomer patterns in male rats. Furthermore, because castration significantly decreases ad libitum food consumption, we investigated the influence of food restriction on lycopene metabolism. Forty male F344 rats 8 wk of age were randomly assigned to one of four treatments (n = 10/group): 1) intact, free access to food, 2) castration, free access to food, 3) castration plus testosterone implants, free access to food and 4) intact, 20% food restricted. All rats were fed an AIN-based diet with 0.25 g lycopene (as 10% water-soluble beadlets)/kg diet for 3 wk. Serum testosterone was 5.31 +/- 1.46 nmol/L in intact controls allowed free access to food, reduced in castrated animals (0.52 +/- 0.10, P < 0.0001 versus controls) and intact, food-restricted rats (1.53 +/- 0.49 nmol/L, P < 0.0001 versus controls) and greater (17.23 +/- 3.09 nmol/L) in castrated rats administered testosterone (P < 0.0001 versus controls). Castrated rats accumulated approximately twice as much liver lycopene (74.5 +/- 8.5 nmol/g; P < 0.01 versus controls) as intact rats allowed free access to food (39.5 +/- 5.0) despite 13% lower dietary lycopene intake (P < 0.001; 3.38 +/- 0.07 versus 3.95 +/- 0.06 mg lycopene/d). Testosterone replacement in castrated rats returned liver lycopene concentrations (32.5 +/- 5.5 nmol lycopene/g with 3.76 +/- 0.05 mg dietary lycopene/d) to those observed in intact rats. Food restriction resulted in a 20% decrease in lycopene intake but significantly increased liver lycopene by 68% (66.3 +/- 7.9 nmol lycopene/g with 3.38 +/- 0.00 mg lycopene/d) compared with controls and castrated rats administered testosterone. These results suggest that androgen depletion and 20% food restriction increase hepatic lycopene accumulation. We hypothesize an endocrine and dietary interaction, where higher androgen concentrations and greater energy intake may stimulate lycopene metabolism and degradation.


Subject(s)
Carotenoids/pharmacokinetics , Food Deprivation , Liver/metabolism , Testosterone/pharmacology , Adrenal Glands/metabolism , Animals , Carotenoids/blood , Carotenoids/metabolism , Castration , Delayed-Action Preparations , Drug Interactions , Eating/drug effects , Energy Metabolism , Growth/drug effects , Isomerism , Lycopene , Male , Rats , Rats, Inbred F344 , Testosterone/administration & dosage , Testosterone/blood
5.
Am J Epidemiol ; 152(12): 1145-53, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11130620

ABSTRACT

Data derived from laboratory investigations suggest that a number of dietary variables may contribute to bladder carcinogenesis. Although bladder cancer is the fourth leading cause of cancer in men in the United States, dietary studies are few. The authors examined the relations between intakes of macro- and micronutrients and the risk of bladder cancer among men in the prospective Health Professionals Follow-Up Study. Each participant completed a 131-item food frequency questionnaire in 1986 and in 1990, from which nutrient intakes were calculated. During 12 years of follow-up, 320 cases of bladder cancer were diagnosed. No association was observed for total caloric or macronutrient intake and bladder cancer risk. Similarly, we found no relation for dietary intake of potassium, sodium, calcium, magnesium, phosphorus, iron, or water-soluble vitamins and bladder cancer risk. Total vitamin E intake and vitamin E supplements were inversely associated with risk. In addition, a dose-response relation was observed for duration of vitamin E supplement use. A suggestive inverse association was seen with dose of vitamin C supplement use. More studies are needed to determine the role of vitamins E and C supplement intake in bladder carcinogenesis.


Subject(s)
Diet/adverse effects , Dietary Supplements , Micronutrients , Urinary Bladder Neoplasms/epidemiology , Urinary Bladder Neoplasms/etiology , Adult , Age Distribution , Aged , Cohort Studies , Humans , Incidence , Logistic Models , Male , Multivariate Analysis , Prospective Studies , Risk Assessment , Risk Factors , Surveys and Questionnaires , United States/epidemiology
6.
Nutr Cancer ; 36(2): 185-90, 2000.
Article in English | MEDLINE | ID: mdl-10890029

ABSTRACT

Cell culture systems provide an opportunity to evaluate the effects of carotenoids on molecular and cellular processes involved in proliferation and differentiation of prostate cancer cells. The stability and cellular uptake of beta-carotene (BC) by prostate cancer cells were investigated in vitro by use of various delivery methods and three human prostate adenocarcinoma cell lines: PC-3, DU 145, and LNCaP. Recovery of BC from the media (prepared from water-dispersible BC beadlets) significantly (p < 0.05) decreased after 12 hours in culture and continued to significantly decrease (p < 0.05) after 24, 48, 72, and 96 hours, an observation primarily attributed to BC degradation rather than isomerization, metabolism, or cellular uptake. The uptake of BC by prostate cancer cells was compared when delivered by tetrahydrofuran, BC-enriched bovine serum, water-dispersible BC beadlets, and artificial liposomes. Recovery of BC after three days in culture from enriched bovine serum medium was significantly (p < 0.05) greater than recovery from medium prepared by beadlets, tetrahydrofuran, or artificial liposomes. We conclude that BC is relatively unstable in vitro and that degradation products may contribute to biological responses. Furthermore, our studies indicate that enriched bovine serum provides a stable and physiological approach to carotenoid treatment of cells in culture.


Subject(s)
Adenocarcinoma/metabolism , Prostatic Neoplasms/metabolism , beta Carotene/metabolism , Animals , Cattle , Culture Media , Drug Delivery Systems/methods , Drug Stability , Furans , Humans , In Vitro Techniques , Lipoproteins , Liposomes , Male , Microspheres , Pharmaceutical Vehicles , Solvents , Time Factors , Tumor Cells, Cultured , beta Carotene/administration & dosage , beta Carotene/chemistry
7.
J Nutr ; 130(6): 1613-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10827218

ABSTRACT

Diets rich in lycopene from tomato products as well as greater concentrations of blood lycopene have been associated with a decreased risk for prostate cancer in epidemiologic studies. However, little is known about factors modulating lycopene absorption, metabolism and tissue distribution in humans and animal models of prostate cancer. A 2 x 4 factorial design was used to measure the effects of androgen status (castrated vs. intact), dietary lycopene concentration (0.00-5.00 g/kg lycopene) and their interaction on tissue lycopene accumulation and isomer patterns in male F344 rats. Male F344 rats ( 14 wk old; 44 castrated, 44 intact) were randomly assigned to one of four diets containing total lycopene concentrations of 0.00, 0.05, 0.50 or 5.00 g/kg as beadlets and fed for 8 wk. Tissue total lycopene and cis/trans lycopene profiles were determined by HPLC. Tissue and serum lycopene concentrations increased significantly (P < 0.01) as dietary lycopene levels increased between 0.00 and 0.50 g/kg. No further increases in serum or tissue concentrations were seen in rats fed dietary lycopene between 0.50 and 5.00 g/kg. As dietary lycopene increased, so did the percentage of cis lycopene in the liver (P < 0.05), due primarily to an increase in the 5-cis isomer. Castrated rats accumulated twice (P < 0.01) the liver lycopene as compared to intact controls, with no effect of castration on serum lycopene or adrenal, kidney, adipose, or lung tissue concentration. Livers from castrated rats had a greater proportion of cis-lycopene than those of intact rats (P < 0.05). A significant interaction between dietary lycopene concentration and androgen status was seen for liver lycopene concentration (P < 0.01). We conclude that serum and tissue lycopene reaches a plateau between 0.05 and 0.50 g/kg dietary lycopene, the tissue cis/trans lycopene ratio increases with greater dietary lycopene and androgens modulate hepatic lycopene metabolism.


Subject(s)
Androgens/blood , Anticarcinogenic Agents/pharmacokinetics , Carotenoids/pharmacokinetics , Diet , Analysis of Variance , Animals , Anticarcinogenic Agents/administration & dosage , Anticarcinogenic Agents/blood , Carotenoids/administration & dosage , Carotenoids/blood , Carotenoids/chemistry , Liver/metabolism , Lycopene , Male , Orchiectomy , Rats , Rats, Inbred F344 , Stereoisomerism , Tissue Distribution
8.
Urol Clin North Am ; 27(1): 147-55, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10696253

ABSTRACT

Despite incomplete understanding of the human immune system, the rapid progress in tumor immunology provides a framework for more effective and safe interventions in the near future. Early approaches in patients with cancer that have focused on the nonspecific and broad stimulation of the immune system by interferons and IL-12 will be replaced by the highly specific stimulation of immune reactions targeting precisely defined tumor antigens. IL-12 has several biologic properties that seem useful in immune therapy for bladder cancer. The striking antitumor responses with IL-12 in preclinical animal models of bladder cancer provide optimism that future clinical trials involving this agent may impact on the risk and mortality associated with this disease.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Interleukin-12/therapeutic use , Urinary Bladder Neoplasms/drug therapy , Adjuvants, Immunologic/pharmacology , BCG Vaccine/therapeutic use , Cancer Vaccines/therapeutic use , Chemotherapy, Adjuvant , Clinical Trials as Topic , Humans , Interleukin-12/pharmacology , Radiotherapy, Adjuvant , Urinary Bladder Neoplasms/immunology
9.
J Nutr ; 130(4): 728-32, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10736321

ABSTRACT

Epidemiologic and animal studies provide support for a relationship between high intakes of carotenoids from fruits and vegetables with reduced risk of several malignancies including prostate cancer. The highly controlled environments of in vitro systems provide an opportunity to investigate the cellular and molecular effects of carotenoids. The effects of beta-carotene (BC) on in vitro growth rates, p21(WAF1) and p53 gene expression, as well as the conversion of BC to retinol were investigated in three human prostate adenocarcinoma cell lines: PC-3, DU 145 and LNCaP. In these experiments, media concentrations of 30 micromol BC/L for 72 h significantly (P < 0.05) slowed in vitro growth rates in all three cell lines, independently of p53 or p21(WAF1) status or expression. (14)C-labeled retinol was detected in prostate tumor cells incubated with (14)C-labeled BC, suggesting metabolic conversion of BC to retinol. Conversely, no (14)C-labeled retinol was detected in media incubated without prostate cancer cells. These studies support a hypothesis that in vitro biological effects of BC on prostate cells may result in part from the conversion of BC to retinol or other metabolites. The possibility that prostate cancer cells in vivo locally metabolize provitamin A carotenoids to retinol and other related metabolites may have implications for our understanding of prostate cancer etiology and the design of future prevention studies.


Subject(s)
Adenocarcinoma/pathology , Intracellular Fluid/metabolism , Prostatic Neoplasms/pathology , Vitamin A/biosynthesis , beta Carotene/physiology , Adenocarcinoma/metabolism , Cell Division/physiology , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/metabolism , Humans , Male , Prostatic Neoplasms/metabolism , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/pathology , Tumor Suppressor Protein p53/metabolism , beta Carotene/metabolism , beta Carotene/pharmacology
11.
J Immunol ; 163(8): 4246-52, 1999 Oct 15.
Article in English | MEDLINE | ID: mdl-10510362

ABSTRACT

Although Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been accepted as the most effective agent in clinical use against superficial bladder cancer, its mechanism of action remains incompletely understood. A kinetic analysis in assessing the potential role of cytokines from BCG-stimulated murine splenocytes showed that IL-12 expression preceded that of other cytokines. Experiments subtracting endogenous BCG-driven IL-12 using neutralizing Ab or augmenting its activity with supplemental rIL-12 revealed not only that IL-12 plays a dominant role in IFN-gamma induction but also that it is normally dose limiting. A striking increase in IFN-gamma production could be generated in both mouse and human immunocompetent cell culture by the addition of even a small amount of rIL-12. Moreover, this same synergistic effect could be replicated during in vivo administration of BCG plus rIL-12 into the mouse bladder and was observed in a patient receiving intravesical combination therapy. In costimulation cultures, this synergy appeared to partially rely on IL-18 and IL-2 and could be down-regulated by IL-10. This suggests that a dynamic interplay between Th1 and Th2 cytokines is responsible for net IFN-gamma production. The ability of supplemental exogenous IL-12 to strongly shift this balance toward Th1 provides an immunological basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy.


Subject(s)
Adjuvants, Immunologic/physiology , Interferon Inducers/immunology , Interferon-gamma/biosynthesis , Interleukin-12/physiology , Mycobacterium bovis/immunology , Adjuvants, Immunologic/administration & dosage , Administration, Intravesical , Animals , Cells, Cultured , Female , Humans , Immune Sera/pharmacology , Interferon Inducers/administration & dosage , Interferon-gamma/blood , Interferon-gamma/urine , Interleukin-12/administration & dosage , Interleukin-12/antagonists & inhibitors , Interleukin-12/immunology , Interleukin-18/antagonists & inhibitors , Interleukin-18/immunology , Interleukin-18/physiology , Interleukin-2/antagonists & inhibitors , Interleukin-2/immunology , Interleukin-2/physiology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Mice , Mice, Inbred C57BL , Spleen/cytology , Spleen/immunology , Spleen/metabolism
12.
J Nutr ; 129(9): 1628-35, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10460196

ABSTRACT

The objectives of our studies are to characterize the ability of dietary soybean components to inhibit the growth of prostate cancer in mice and alter tumor biomarkers associated with angiogenesis. Soy isoflavones (genistein or daidzein) or soy phytochemical concentrate inhibit the growth of prostate cancer cells LNCaP, DU 145 and PC-3 in vitro, but only at supraphysiologic concentrations, i.e., 50% inhibitory concentration (IC(50)) > 50 micromol/L. G2-M arrest and DNA fragmentation consistent with apoptosis of prostate cancer cells are also observed at concentrations causing growth inhibition. In contrast, the in vitro proliferation of vascular endothelial cells was inhibited by soy phytochemcials at much lower concentrations. We evaluated the ability of dietary soy phytochemical concentrate and soy protein isolate to inhibit the growth of the LNCaP human prostate cancer in severe combined immune-deficient mice. Mice inoculated subcutaneously with LNCaP cells (2 x 10(6)) were randomly assigned to one of the six dietary groups based on the AIN-76A formulation for 3 wk. A 2 x 3 factorial design was employed with two protein sources (20%, casein vs. soy protein) and three levels of soy phytochemical concentrate (0, 0.2 and 1.0% of the diet). Soy components did not alter body weight gain or food intake. Compared with casein-fed controls, the tumor volumes after 3 wk were reduced by 11% (P = 0.45) by soy protein, 19% (P = 0.17) by 0.2% soy phytochemical concentrate, 28% by soy protein with 0.2% soy phytochemical concentrate (P < 0.05), 30% by 1.0% soy phytochemical concentrate (P < 0.05) and 40% by soy protein with 1.0% soy phytochemical concentrate (P < 0.005). Histologic examination of tumor tissue showed that consumption of soy products significantly reduced tumor cell proliferation, increased apoptosis and reduced microvessel density. The angiogenic protein insulin-like growth factor-I was reduced in the circulation of mice fed soy protein and phytochemical concentrate. Our data suggest that dietary soy products may inhibit experimental prostate tumor growth through a combination of direct effects on tumor cells and indirect effects on tumor neovasculature.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma/drug therapy , Glycine max/therapeutic use , Phytotherapy , Prostatic Neoplasms/drug therapy , Soybean Proteins/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Carcinoma/blood supply , Carcinoma/pathology , Cell Count , Cell Cycle/drug effects , DNA Fragmentation/drug effects , Dose-Response Relationship, Drug , Endothelium/drug effects , Genistein/isolation & purification , Genistein/pharmacology , Genistein/therapeutic use , Humans , Immunohistochemistry , Insulin-Like Growth Factor I/analysis , Male , Mice , Mice, SCID , Neoplasm Transplantation , Neovascularization, Pathologic/drug therapy , Proliferating Cell Nuclear Antigen/analysis , Prostatic Neoplasms/blood supply , Prostatic Neoplasms/pathology , Soybean Proteins/pharmacology , Glycine max/chemistry , Tumor Cells, Cultured
13.
Arterioscler Thromb Vasc Biol ; 19(8): 1938-44, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10446074

ABSTRACT

Past studies of atherosclerosis in mice have used chow-based diets supplemented with cholesterol, lipid, and sodium cholate to overcome species resistance to lesion formation. Similar diets have been routinely used in studies with LDL receptor-deficient (LDLR(-/-)) mice. The nonphysiological nature and potential toxicity of cholate-containing diets have led to speculation that atherogenesis in these mice may not accurately reflect the human disease process. We have designed a semipurified AIN-76A-based diet that can be fed in powdered, pelleted, or liquid form and manipulated for the precise evaluation of diet-genetic interactions in murine atherosclerosis. LDLR(-/-) mice were randomly assigned among 4 diets (n=6/diet) as follows: 1, control, 10% kcal lipid; 2, high fat (40% kcal), moderate cholesterol (0.5% by weight); 3, high fat, high cholesterol (1.25% by weight); and 4, high fat, high cholesterol, and 0.5% (wt/wt) sodium cholate. Fasting serum cholesterol was increased in all cholesterol-supplemented mice compared with controls after 6 or 12 weeks of feeding (P<0.01). The total area of oil red O-stained atherosclerotic lesions was determined from digitally scanned photographs. In contrast to the control group, all mice in cholesterol-supplemented dietary groups 2 to 4 had lesions involving 7.01% to 12.79% area of the thoracic and abdominal aorta at 12 weeks (P<0.002, for each group versus control). The distribution pattern of atherosclerotic lesions was highly reproducible and comparable. The histological features of lesions in mice fed cholate-free or cholate-containing diets were similar. This study shows that sodium cholate is not necessary for the formation of atherosclerosis in LDLR(-/-) mice and that precisely defined semipurified diets are a valuable tool for the examination of diet-gene interactions.


Subject(s)
Arteriosclerosis/etiology , Cholates/administration & dosage , Hyperlipidemias/etiology , Receptors, LDL/deficiency , Animal Feed , Animals , Aorta/pathology , Body Weight , Diet , Lipids/blood , Liver/anatomy & histology , Liver/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic
14.
N Engl J Med ; 340(18): 1390-7, 1999 May 06.
Article in English | MEDLINE | ID: mdl-10228189

ABSTRACT

BACKGROUND: Studies in animals have shown that the frequency of urination is inversely associated with the level of potential carcinogens in the urothelium. In humans, an increase in total fluid intake may reduce contact time between carcinogens and urothelium by diluting urinary metabolites and increasing the frequency of voiding. The data on fluid intake in relation to the risk of bladder cancer are inconclusive. METHODS: We examined the relation between total fluid intake and the risk of bladder cancer over a period of 10 years among 47,909 participants in the prospective Health Professionals Follow-up Study. There were 252 newly diagnosed cases of bladder cancer during the follow-up period. Information on total fluid intake was derived from the reported frequency of consumption of the 22 types of beverages on the food-frequency questionnaire, which was completed by each of the 47,909 participants who were free of cancer in 1986. Logistic-regression analyses were performed to adjust for known and suspected risk factors for bladder cancer. RESULTS: Total daily fluid intake was inversely associated with the risk of bladder cancer; the multivariate relative risk was 0.51 (95 percent confidence interval, 0.32 to 0.80) for the highest quintile of total daily fluid intake (>2531 ml per day) as compared with the lowest quintile (<1290 ml per day). The consumption of water contributed to a lower risk (relative risk, 0.49 [95 percent confidence interval, 0.28 to 0.86] for > or =1440 ml [6 cups] per day vs. <240 ml [1 cup] per day), as did the consumption of other fluids (relative risk, 0.63 [95 percent confidence interval, 0.39 to 0.99] for >1831 ml per day vs. <735 ml per day). CONCLUSIONS: A high fluid intake is associated with a decreased risk of bladder cancer in men.


Subject(s)
Drinking , Urinary Bladder Neoplasms/epidemiology , Adult , Aged , Alcoholic Beverages/statistics & numerical data , Caffeine/administration & dosage , Cohort Studies , Diet Surveys , Humans , Incidence , Male , Middle Aged , Multivariate Analysis , Risk , Risk Factors , Surveys and Questionnaires , United States/epidemiology , Urinary Bladder Neoplasms/prevention & control , Water/administration & dosage
15.
J Natl Cancer Inst ; 91(7): 605-13, 1999 Apr 07.
Article in English | MEDLINE | ID: mdl-10203279

ABSTRACT

BACKGROUND: Previous epidemiologic studies of fruit and vegetable intake and bladder cancer risk have yielded inconsistent results, especially with regard to the types of fruits and vegetables consumed. We examined total fruit and vegetable intake, as well as intakes of subtypes of fruits and vegetables, in relation to bladder cancer risk in a large male prospective cohort study. METHODS: Two hundred fifty-two cases of incident bladder cancer were diagnosed from 1986 through January 31, 1996, among 47,909 men enrolled in the Health Professionals Follow-up Study. Each participant in this cohort completed a 131-item food-frequency questionnaire in 1986 and subsequently in 1990 and 1994. We used logistic regression analyses to examine fruit and vegetable intake in relation to bladder cancer risk, after adjusting for age, history of cigarette smoking, current smoking status, geographic region, total fluid intake, and caloric intake. RESULTS: We observed a weak, inverse association that was not statistically significant between total fruit and vegetable intake and bladder cancer risk. Intake of cruciferous vegetables was inversely associated with risk (relative risk = 0.49; 95% confidence interval = 0.32-0.75, for the highest category of cruciferous vegetable intake compared with the lowest), but intakes of yellow or green leafy vegetables or carotenoid-rich vegetables were not associated with risk. Individual cruciferous vegetables, except for coleslaw, were all inversely related to bladder cancer risk, but only the associations for broccoli and cabbage were statistically significant. CONCLUSIONS: Data from this study indicate that high cruciferous vegetable consumption may reduce bladder cancer risk, but other vegetables and fruits may not confer appreciable benefits against this cancer.


Subject(s)
Fruit , Urinary Bladder Neoplasms/epidemiology , Urinary Bladder Neoplasms/prevention & control , Vegetables , Adult , Aged , Humans , Incidence , Logistic Models , Male , Middle Aged , Prospective Studies , Risk , Surveys and Questionnaires , United States/epidemiology
16.
J Natl Cancer Inst ; 91(6): 512-23, 1999 Mar 17.
Article in English | MEDLINE | ID: mdl-10088621

ABSTRACT

BACKGROUND: A sedentary lifestyle coupled with excessive energy intake is speculated to be a factor associated with increased incidence of prostate cancer. We have investigated the effects of energy intake on prostate tumor growth in experimental animals. METHODS: Two transplantable prostate tumor models, i.e., the androgen-dependent Dunning R3327-H adenocarcinoma in rats and the androgen-sensitive LNCaP human carcinoma in severe combined immunodeficient mice, were studied. R3327-H tumor growth and relevant tumor biomarkers (proliferation index, apoptosis [programmed cell death], microvessel density, and vascular endothelial growth factor [VEGF] expression) were compared in ad libitum fed control rats, ad libitum fed castrated rats, and groups restricted in energy intake by 20% or 40%. A second set of experiments involving both tumor models examined tumor growth in ad libitum fed rats or in animals whose energy intake was restricted by 30% using three different methods, i.e., total diet restriction, carbohydrate restriction, or lipid restriction. All P values are two-sided. RESULTS: R3327-H tumors were smaller in energy-restricted or castrated rats than in control rats (P<.001). Tumors from energy-restricted rats exhibited changes in tumor architecture characterized by increased stroma and more homogeneous and smaller glands. In castrated rats, the tumor proliferation index was reduced (P<.0001), whereas apoptosis was increased in both energy-restricted (P<.001) and castrated (P<.001) rats. Tumor microvessel density and VEGF expression were reduced by energy restriction and castration (P<.003 versus control). Restriction of energy intake by reduction of carbohydrate intake, lipid intake, or total diet produced a similar inhibition of growth of R3327-H or LNCaP tumors. These effects were associated with reduced circulating insulin-like growth factor-I. CONCLUSIONS: Our observations are consistent with the hypothesis that energy restriction reduces prostate tumor growth by inhibiting tumor angiogenesis. Furthermore, dietary fat concentration does not influence prostate tumor growth when energy intake is reduced.


Subject(s)
Adenocarcinoma , Apoptosis , Endothelial Growth Factors/biosynthesis , Energy Intake , Gene Expression Regulation, Neoplastic , Lymphokines/biosynthesis , Neovascularization, Pathologic , Prostatic Neoplasms , Adenocarcinoma/blood supply , Adenocarcinoma/etiology , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Cell Division , Humans , Insulin-Like Growth Factor I/metabolism , Male , Mice , Mice, SCID , Microcirculation , Prostatic Neoplasms/blood supply , Prostatic Neoplasms/etiology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Rats , Rats, Inbred Strains , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
17.
Cancer Res ; 58(22): 5231-8, 1998 Nov 15.
Article in English | MEDLINE | ID: mdl-9823337

ABSTRACT

Soy isoflavones exhibit a number of biological effects, suggesting that they may have a role in cancer prevention. Our objectives are to determine whether components of soy products or purified soy isoflavones can inhibit the progression of bladder cancer. We compared the in vitro effects of pure soy isoflavones and soy phytochemical concentrate on growth curves, cell cycle progression, and apoptosis in murine and human bladder cancer cell lines. Pure soy isoflavones (genistein, genistin, daidzein, and biochanin A) and soy phytochemical concentrate exhibit dose-dependent growth inhibition of murine (MB49 and MBT-2) and human (HT-1376, UM-UC-3, RT-4, J82, and TCCSUP) bladder cancer cell lines, although the degree of inhibition varies among lines. Soy isoflavones induce a G2-M cell cycle arrest in all human and murine lines evaluated by flow cytometry. In addition, some bladder cancer lines show DNA fragmentation consistent with apoptosis. We next evaluated the ability of genistein, soy phytochemical concentrate, and soy protein isolate, respectively, to inhibit the growth of transplantable murine bladder cancer in vivo. C57BL/6 mice were randomly assigned to treatment groups (n = 12/group): (a) AIN-76A diet; (b) AIN-76A diet plus genistein, i.p., 50 mg/kg body weight/day; (c) AIN-76 diet with soy phytochemical concentrate at 0.2% of the diet; (d) AIN-76 diet with soy phytochemical concentrate at 1.0% of the diet; and (e) AIN-76A diet with soy protein isolate, 20% by weight. Mice were inoculated s.c. with 5 x 10(4) syngeneic MB49 bladder carcinoma cells, and tumor growth was quantitated. Neither genistein nor soy products reduced body weight gain. Tumor volumes from mice treated with genistein, dietary soy phytochemical concentrate at 1%, or dietary soy protein isolate were reduced by 40% (P < 0.007), 48% (P < 0.001), or 37% (P < 0.01), respectively, compared with controls. We characterized the effects of treatment on several biomarkers in tumor tissue: proliferation index by proliferating cell nuclear antigen staining, apoptotic index by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling staining, and angiogenesis by microvessel quantitation. Soy products reduced angiogenesis, increased apoptosis, and slightly reduced proliferation while showing no histopathological effects on the normal bladder mucosa. Our data suggest that soy isoflavones can inhibit bladder tumor growth through a combination of direct effects on tumor cells and indirect effects on the tumor neovasculature. Soy products warrant further investigation in bladder cancer prevention and treatment programs or as antiangiogenic agents.


Subject(s)
Anticarcinogenic Agents/pharmacology , Urinary Bladder Neoplasms/prevention & control , Animals , Apoptosis/genetics , Cell Cycle/drug effects , DNA Fragmentation , DNA, Neoplasm/drug effects , Drug Screening Assays, Antitumor , Female , Genistein/pharmacology , Humans , Isoflavones/pharmacology , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Neovascularization, Pathologic/prevention & control , Tumor Cells, Cultured/drug effects , Urinary Bladder Neoplasms/blood supply
18.
Mol Cell ; 2(2): 275-81, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9734366

ABSTRACT

Recruitment of blood monocytes into the arterial subendothelium is one of the earliest steps in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1), a CC chemokine, is one likely signal involved in this process. To test MCP-1's role in atherogenesis, low density lipoprotein (LDL) receptor-deficient mice were made genetically deficient for MCP-1 and fed a high cholesterol diet. Despite having the same amount of total and fractionated serum cholesterol as LDL receptor-deficient mice with wild-type MCP-1 alleles, LDL receptor/MCP-1-deficient mice had 83% less lipid deposition throughout their aortas. Consistent with MCP-1 's monocyte chemoattractant properties, compound-deficient mice also had fewer macrophages in their aortic walls. Thus, MCP-1 plays a unique and crucial role in the initiation of atherosclerosis and may provide a new therapeutic target in this disorder.


Subject(s)
Arteriosclerosis/prevention & control , Chemokine CCL2/deficiency , Receptors, LDL/deficiency , Animals , Aorta/metabolism , Aorta/pathology , Arteriosclerosis/etiology , Arteriosclerosis/physiopathology , Base Sequence , Cell Movement , Chemokine CCL2/genetics , Chemokine CCL2/physiology , DNA Primers/genetics , Diet, Atherogenic , Female , Lipid Metabolism , Lipids/blood , Macrophages/pathology , Macrophages/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Monocytes/physiology , Polymerase Chain Reaction
19.
Annu Rev Nutr ; 18: 413-40, 1998.
Article in English | MEDLINE | ID: mdl-9706231

ABSTRACT

Cancer of the prostate gland is one of the most common malignancies in affluent nations, in part due to the application of new screening and diagnostic tools. The development of life-threatening prostate cancer is the culmination of a complex series of initiation and promotional events over a period of decades and under the influence of many interacting genetic and environmental factors. A rapidly accumulating scientific literature provides compelling evidence for the hypothesis that diet and nutrition are important factors modifying risk of prostate cancer. Additional resources devoted to interactive research efforts by laboratory scientists and epidemiologists will provide further enlightenment and continued refinement of our assessment of risks and benefits for specific nutrients and dietary patterns. These studies provide hope that evidence-based dietary interventions will significantly impact the risk of prostate cancer and enhance the efficacy of therapeutic interventions.


Subject(s)
Diet , Nutritional Physiological Phenomena , Prostatic Neoplasms , Animals , Humans , Male , Prostatic Neoplasms/etiology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Risk Factors
20.
Circulation ; 97(24): 2433-44, 1998 Jun 23.
Article in English | MEDLINE | ID: mdl-9641696

ABSTRACT

BACKGROUND: Proteolytic enzyme activity in lipid-rich atheroma may promote plaque rupture and precipitate acute coronary syndromes. This study tested the hypothesis that lipid lowering stabilizes plaques by reducing proteolytic activity. METHODS AND RESULTS: We produced experimental atheroma in 33 rabbits by balloon injury and an atherogenic diet (0.3% cholesterol and 4.7% coconut oil) for 4 months. At that time, 15 rabbits were killed (baseline group). The remaining animals were divided into two groups: a hyperlipemic group continued to consume a cholesterol-enriched diet (0.05% to 0.2%) for 16 more months (n=5) and a lipid-lowering group consumed a purified chow diet with no added cholesterol or fat for 8 (n=3) or 16 months (n=10). Macrophage accumulation and interstitial collagenase (matrix metalloproteinase-1, MMP-1) expression in the lesion were measured by quantitative image analysis of standardized sections of immunostained aortas. Baseline lesions expressed high levels of MMP-1 and contained many macrophages. These features of plaque instability persisted in the hyperlipemic group. However, the lipid-lowering group showed progressive reduction in both macrophage content and MMP- 1 immunoreactivity with time. Aortic rings of the baseline and hyperlipemic groups elaborated gelatinolytic, caseinolytic, and elastinolytic activity attributable to MMP-2, MMP-3, or MMP-9, monitored by SDS-PAGE zymography. Proteolytic activity decreased markedly in the lipid-lowering group. Aortic content of interstitial collagen, determined by sirius red staining, increased in the lipid-lowering group compared with the baseline or continued hyperlipemic groups, indicating that lipid lowering reinforced the fibrous skeleton of the atheroma. CONCLUSIONS: These results establish a mechanism by which lipid lowering may stabilize vulnerable plaques by reduced expression and activity of enzymes that degrade the arterial extracellular matrix and render atheroma less susceptible to disruption and thrombosis by favoring collagen accumulation in the fibrous cap.


Subject(s)
Arteriosclerosis/metabolism , Collagen/metabolism , Diet, Fat-Restricted , Metalloendopeptidases/metabolism , Animals , Aorta/pathology , Arteriosclerosis/enzymology , Arteriosclerosis/pathology , Cholesterol, Dietary/administration & dosage , Diet, Atherogenic , Hypercholesterolemia/diet therapy , Hypercholesterolemia/metabolism , Macrophages/metabolism , Male , Rabbits
SELECTION OF CITATIONS
SEARCH DETAIL
...